Colon Cancer – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 2 PAGES: 219

More Info
									Colon Cancer – Pipeline Review, H1 2012




                      Colon Cancer – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1638IDB
                                                                                            Publication Date: January 2012




Colon Cancer – Pipeline Review, H1 2012                                                    GMDHC1638IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Colon Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 9
    List of Figures .............................................................................................................................................................................. 12
Introduction....................................................................................................................................................................................... 13
    Global Markets Direct Report Coverage ...................................................................................................................................... 13
Colon Cancer Overview.................................................................................................................................................................... 14
Therapeutics Development............................................................................................................................................................... 15
    An Overview of Pipeline Products for Colon Cancer ................................................................................................................... 15
Colon Cancer Therapeutics under Development by Companies ...................................................................................................... 17
Colon Cancer Therapeutics under Investigation by Universities/Institutes ....................................................................................... 24
Late Stage Products ......................................................................................................................................................................... 29
    Comparative Analysis .................................................................................................................................................................. 29
Mid Clinical Stage Products.............................................................................................................................................................. 30
    Comparative Analysis .................................................................................................................................................................. 30
Early Clinical Stage Products ........................................................................................................................................................... 31
    Comparative Analysis .................................................................................................................................................................. 31
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 32
    Comparative Analysis .................................................................................................................................................................. 32
Colon Cancer Therapeutics – Products under Development by Companies .................................................................................... 33
Colon Cancer Therapeutics – Products under Investigation by Universities/Institutes ..................................................................... 40
Companies Involved in Colon Cancer Therapeutics Development................................................................................................... 46
    Kyowa Hakko Kirin Co., Ltd. ........................................................................................................................................................ 46
    Eli Lilly and Company .................................................................................................................................................................. 47
    Albany Molecular Research, Inc. ................................................................................................................................................. 48
    Labopharm Inc............................................................................................................................................................................. 49
    Celltrion, Inc................................................................................................................................................................................. 50
    Prolexys Pharmaceuticals, Inc..................................................................................................................................................... 51
    Bio-Path Holdings, Inc. ................................................................................................................................................................ 52
    ZIOPHARM Oncology, Inc. .......................................................................................................................................................... 53
    Fox Chase Cancer Center ........................................................................................................................................................... 54
    ImClone Systems Incorporated ................................................................................................................................................... 55
    Enzon Pharmaceuticals, Inc. ....................................................................................................................................................... 56
    Alfacell Corporation ..................................................................................................................................................................... 57
    Access Pharmaceuticals, Inc. ...................................................................................................................................................... 58
    Alchemia Limited ......................................................................................................................................................................... 59
    EntreMed, Inc. ............................................................................................................................................................................. 60
    GW Pharmaceuticals plc ............................................................................................................................................................. 61
    Enzo Biochem, Inc....................................................................................................................................................................... 62
    ImmunoCellular Therapeutics, Ltd. .............................................................................................................................................. 63
    Lorus Therapeutics Inc ................................................................................................................................................................ 64
    Bio-Bridge Science, Inc. .............................................................................................................................................................. 65
    Bionomics Limited ....................................................................................................................................................................... 66



Colon Cancer – Pipeline Review, H1 2012                                                                                                      GMDHC1638IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Colon Cancer – Pipeline Review, H1 2012



    Neuren Pharmaceuticals Limited ................................................................................................................................................. 67
    Cleveland BioLabs, Inc. ............................................................................................................................................................... 68
    OncoVista Innovative Therapies, Inc. .......................................................................................................................................... 69
    Compugen Ltd. ............................................................................................................................................................................ 70
    Patrys Limited .............................................................................................................................................................................. 71
    Cosmo Pharmaceuticals S.p.A .................................................................................................................................................... 72
    Critical Outcome Technologies Inc. ............................................................................................................................................. 73
    Curis, Inc. .................................................................................................................................................................................... 74
    Telik, Inc. ..................................................................................................................................................................................... 75
    Dendreon Corporation ................................................................................................................................................................. 76
    Green Cross Corporation ............................................................................................................................................................ 77
    CrystalGenomics, Inc. ................................................................................................................................................................. 78
    Sareum Holdings plc ................................................................................................................................................................... 79
    Rexahn Pharmaceuticals, Inc. ..................................................................................................................................................... 80
    SymBio Pharmaceuticals Limited ................................................................................................................................................ 81
    MabVax Therapeutics, Inc. .......................................................................................................................................................... 82
    Antisense Pharma GmbH ............................................................................................................................................................ 83
    Immupharma Plc ......................................................................................................................................................................... 84
    Actinium Pharmaceuticals, Inc..................................................................................................................................................... 85
    Indena S.p.A. ............................................................................................................................................................................... 86
    InterMed Discovery GmbH .......................................................................................................................................................... 87
    Provecs Medical GmbH ............................................................................................................................................................... 88
    Alethia Biotherapeutics Inc. ......................................................................................................................................................... 89
    NormOxys, Inc. ............................................................................................................................................................................ 90
    MacroGenics, Inc......................................................................................................................................................................... 91
    OncoMed Pharmaceuticals, Inc. .................................................................................................................................................. 92
    Conatus Pharmaceuticals Inc. ..................................................................................................................................................... 93
    ProNAi Therapeutics, Inc............................................................................................................................................................. 94
    Mersana Therapeutics, Inc. ......................................................................................................................................................... 95
    Affichem ...................................................................................................................................................................................... 96
    Jennerex Biotherapeutics, Inc. .................................................................................................................................................... 97
    Advenchen Laboratories, LLC ..................................................................................................................................................... 98
    Myriad Pharmaceuticals, Inc........................................................................................................................................................ 99
    Xencor, Inc. ............................................................................................................................................................................... 100
    Vaccinogen, Inc. ........................................................................................................................................................................ 101
    Globeimmune, Inc. .................................................................................................................................................................... 102
    APEIRON Biologics AG ............................................................................................................................................................. 103
    Etubics Corporation ................................................................................................................................................................... 104
    NewLink Genetics Corporation .................................................................................................................................................. 105
    Taiwan Liposome Company ...................................................................................................................................................... 106
    TVAX Biomedical, LLC .............................................................................................................................................................. 107
    Viventia Biotechnologies Inc. ..................................................................................................................................................... 108
    Phytomedics, Inc. ...................................................................................................................................................................... 109
    Merus B.V. ................................................................................................................................................................................. 110


Colon Cancer – Pipeline Review, H1 2012                                                                                                       GMDHC1638IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(3)
Colon Cancer – Pipeline Review, H1 2012



    Pique Therapeutics.................................................................................................................................................................... 111
    Cellceutix Pharmaceuticals, Inc. ................................................................................................................................................ 112
    Celtic Pharmaceutical Holdings L.P........................................................................................................................................... 113
    ISA Pharmaceuticals B.V. ......................................................................................................................................................... 114
    ImQuest Life Sciences ............................................................................................................................................................... 115
    TAU Therapeutics, LLC ............................................................................................................................................................. 116
    Immunovative Therapies, Ltd. ................................................................................................................................................... 117
    Oncozyme Pharma Inc. ............................................................................................................................................................. 118
    CytomX, LLC. ............................................................................................................................................................................ 119
Colon Cancer – Therapeutics Assessment .................................................................................................................................... 120
    Assessment by Monotherapy Products ..................................................................................................................................... 120
    Assessment by Combination Products ...................................................................................................................................... 121
    Assessment by Route of Administration .................................................................................................................................... 122
    Assessment by Molecule Type .................................................................................................................................................. 124
Drug Profiles................................................................................................................................................................................... 127
    Erbitux - Drug Profile ................................................................................................................................................................. 127
        Product Description............................................................................................................................................................... 127
        Mechanism of Action ............................................................................................................................................................. 127
        R&D Progress ....................................................................................................................................................................... 127
    OncoVAX - Drug Profile ............................................................................................................................................................. 128
        Product Description............................................................................................................................................................... 128
        Mechanism of Action ............................................................................................................................................................. 128
        R&D Progress ....................................................................................................................................................................... 128
    Rosuvastatin - Drug Profile ........................................................................................................................................................ 130
        Product Description............................................................................................................................................................... 130
        Mechanism of Action ............................................................................................................................................................. 130
        R&D Progress ....................................................................................................................................................................... 130
    5-Fluorouracil + Leucovorin Calcium + Oxaliplatin + Bevacizumab - Drug Profile ..................................................................... 132
        Product Description............................................................................................................................................................... 132
        Mechanism of Action ............................................................................................................................................................. 132
        R&D Progress ....................................................................................................................................................................... 133
    Fluorouracil + Leucovorin + Oxaliplatin - Drug Profile ............................................................................................................... 134
        Product Description............................................................................................................................................................... 134
        Mechanism of Action ............................................................................................................................................................. 134
        R&D Progress ....................................................................................................................................................................... 134
    Carboplatin + 5-Fluorouracil + Leucovorin - Drug Profile........................................................................................................... 136
        Product Description............................................................................................................................................................... 136
        Mechanism of Action ............................................................................................................................................................. 136
        R&D Progress ....................................................................................................................................................................... 136
    Fluorouracil + Leucovorin - Drug Profile .................................................................................................................................... 138
        Product Description............................................................................................................................................................... 138
        Mechanism of Action ............................................................................................................................................................. 138
        R&D Progress ....................................................................................................................................................................... 138
    FOLFOX-4 - Drug Profile ........................................................................................................................................................... 139


Colon Cancer – Pipeline Review, H1 2012                                                                     
								
To top